Clinical trials: Moderate-to-severe Psoriasis
Plaque Psoriasis
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
- Trial name
- ICONIC-LEAD (NCT06095115)
- Testing
- JNJ-77242113
- Where
- 170 sites in United States, Argentina and 14 more
- Volunteers
- 684 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis
The objectives of this study were to evaluate the usability of the combination product of risankizumab in an autoinjector (AI), as well as to evaluate the efficacy, safety, and tolerability of risankizumab administered by AI for…
- Trial name
- NCT03875508
- Testing
- Risankizumab, Autoinjector
- Where
- 26 sites in United States
- Volunteers
- 108 people
- Sponsor
- AbbVie
Plaque Psoriasis
Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis
This is a randomized, double-blind, placebo-controlled, multicenter clinical trial in participants with moderate-to-severe plaque psoriasis .
- Trial name
- NCT06278350
- Testing
- D-2570
- Where
- China
- Volunteers
- 161 people
- Sponsor
- InventisBio Co., Ltd
Psoriasis
Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis
This is a single-center, open-label, pilot study. A total of 30 subjects (15 in each study arm) will be enrolled in this 6 month study to evaluate whether the addition of narrow band UVB (NB-UVB) phototherapy can enhance the…
- Trial name
- NCT00800982
- Testing
- Narrow band (310-312 nm) ultraviolet light B phototherapy, etanercept
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Psoriasis
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- LIMMITLESS (NCT03047395)
- Testing
- risankizumab
- Where
- 233 sites in United States, Australia and 15 more
- Volunteers
- 2,170 people
- Sponsor
- AbbVie
Plaque Psoriasis, Psoriasis Vulgaris
Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
The trial investigates the efficacy and safety of brodalumab against guselkumab in treatment for patients with moderate-to-severe plaque psoriasis who still have some remaining symptoms after ustekinumab treatment.
- Conditions
- Plaque Psoriasis, Psoriasis Vulgaris, Psoriasis
- Trial name
- COBRA (NCT04533737)
- Testing
- Brodalumab, Guselkumab
- Where
- 65 sites in Austria, Belgium and 10 more
- Volunteers
- 113 people
- Sponsor
- LEO Pharma
Moderate to Severe Plaque Psoriasis
Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis
This is a Phase 2b, randomized, multicenter, double-blind, placebo-controlled, multiple-dose study designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with moderate to severe plaque…
- Trial name
- NCT04999839
- Testing
- NDI-034858 study drug
- Where
- 69 sites in United States, Canada
- Volunteers
- 259 people
- Sponsor
- Takeda
Psoriasis
A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis
This is a randomized, placebo-controlled, ascending single dose study of KHK4827 to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous or intravenous administration of KHK4827 in healthy male…
- Trial name
- NCT01488201
- Testing
- KHK4827
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Psoriasis
Study to Evaluate Broadlumab vs Placebo and Ustekinumab
The purpose of the study is to evaluate the efficacy and safety of Induction and Maintenance Regimens of Brodalumab compared with Placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis.
- Trial name
- AMAGINE-3 (NCT02786732)
- Testing
- 210mg Brodalumab, 140mg Brodalumab, Ustekinumab
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- MedDerm Associates
Plaque Psoriasis
An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis
This is a randomized single-blind comparative parallel group efficacy and safety study of ustekinumab biosimilar GNR-068 (45 mg) and reference product Stelara® (45 mg) in the treatment of patients with moderate and severe forms…
- Trial name
- NCT06488664
- Testing
- GNR-068, Stelara®
- Where
- 34 sites in Russia
- Volunteers
- 422 people
- Sponsor
- AO GENERIUM
Psoriasis
A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis
The purpose of this study is to evaluate the efficacy (good or bad effects) and safety of ustekinumab in the treatment of patients with moderate to severe psoriasis in China.
- Trial name
- NCT01008995
- Testing
- ustekinumab
- Where
- 9 sites in China
- Volunteers
- 322 people
- Sponsor
- Centocor, Inc.
Moderate to Severe Chronic Plaque Psoriasis
A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a phase II, randomised, double-blind, placebo-controlled, multiple-dose, multi-center study of AbGn-168H in subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT02223039
- Testing
- AbGn-168H
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Psoriasis
BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, placebo controlled, parallel design study that is being performed to assess the safety and efficacy of BI 655066 (risankizumab).
- Trial name
- NCT03000075
- Testing
- risankizumab
- Volunteers
- 182 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis
This is a two-arm, parallel group, double-blind, placebo-controlled proof-of-concept study comparing 3 mg/kg of AIN457 to placebo.
- Trial name
- NCT00669916
- Testing
- AIN457
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
Study to evaluate pharmacokinetics, efficacy, safety and immunogenicity of multiple switches between Humira® and ABP 501 (new high concentration formulation) compared with continued use of Humira® in participants with moderate to…
- Trial name
- NCT05073315
- Testing
- Adalimumab, ABP 501
- Where
- 88 sites in United States, Canada and 4 more
- Volunteers
- 425 people
- Sponsor
- Amgen
Psoriasis
Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis
CALYPSO clinical study is a phase 3 study which is carried out to establish the efficacy, safety and pharmacokinetic equivalence of BCD-055 (adalimumab, manufactured by JSC BIOCAD, Russia) and Humira® when used in patients with…
- Trial name
- CALYPSO (NCT02762955)
- Testing
- BCD-057, Humira®
- Where
- Russia
- Volunteers
- 344 people
- Sponsor
- Biocad
Plaque Psoriasis
A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany
The purpose of this observational study is to describe the effectiveness of deucravacitinib treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine clinical practice in Germany over a 5-year…
- Trial name
- DELPHIN (NCT06104644)
- Testing
- Deucravacitinib
- Where
- 2 sites in Germany
- Volunteers
- 550 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of initial single and multiple subcutaneous injections of CNTO 1275 in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT00320216
- Testing
- Ustekinumab
- Volunteers
- 320 people
- Sponsor
- Centocor, Inc.
Psoriasis
Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis
The primary objective of Study M16-009 was to investigate the safety of risankizumab in participants with moderate to severe chronic plaque psoriasis who were receiving long-term treatment.
- Trial name
- NCT02203851
- Testing
- Risankizumab
- Volunteers
- 110 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque Psoriasis
The main purpose of this study is to assess how-well COL-5671-PRO works (clinical efficacy), how safe it is (safety), and how well it is tolerated (tolerability) when compared to placebo (a look-alike substance that contains no…
- Trial name
- NCT07914231
- Testing
- COL-5671-PRO
- Where
- 6 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Coultreon Biopharma